{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:56:11Z","timestamp":1790546171079,"version":"4.1.0"},"reference-count":151,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LTGY23H160001"],"award-info":[{"award-number":["LTGY23H160001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["2018ZX10711001"],"award-info":[{"award-number":["2018ZX10711001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e33179","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T19:58:14Z","timestamp":1718654294000},"page":"e33179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19"],"prefix":"10.1016","volume":"10","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Ping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4943-5166","authenticated-orcid":false,"given":"Li-Guo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.heliyon.2024.e33179_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"10224","key":"10.1016\/j.heliyon.2024.e33179_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33179_bib3","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1164\/rccm.202003-0541OC","article-title":"Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium","volume":"202","author":"Zhang","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41588-020-00759-x","article-title":"A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection","volume":"53","author":"Blume","year":"2021","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","year":"2020","journal-title":"Nat Microbiol"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33179_bib8","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JVI.02114-07","article-title":"Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design","volume":"82","author":"Xue","year":"2008","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"7807","key":"10.1016\/j.heliyon.2024.e33179_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat. Commun."},{"issue":"7835","key":"10.1016\/j.heliyon.2024.e33179_bib12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33179_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33179_bib15","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1128\/IAI.70.12.7136-7139.2002","article-title":"The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo","volume":"70","author":"Sarac","year":"2002","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib16","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1038\/s41467-020-19770-1","article-title":"Architecture of a SARS-CoV-2 mini replication and transcription complex","volume":"11","author":"Yan","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/nar\/gkp904","article-title":"The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent","volume":"38","author":"te Velthuis","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33179_bib18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41568-022-00514-w","article-title":"3D bioprinted cancer models: from basic biology to drug development","volume":"22","author":"Neufeld","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902026","article-title":"Hydrogel bioink reinforcement for additive manufacturing: a focused review of emerging strategies","volume":"32","author":"Chimene","year":"2020","journal-title":"Adv. Mater."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e33179_bib20","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33179_bib21","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1742-4658.2006.05130.x","article-title":"The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain","volume":"273","author":"Shi","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.heliyon.2024.e33179_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114076","article-title":"Clinical translation of advanced colonic drug delivery technologies","volume":"181","author":"Awad","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e33179_bib23","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1056\/NEJMc2001801","article-title":"Covid-19 in South Korea - challenges of subclinical manifestations","volume":"382","author":"Song","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10223","key":"10.1016\/j.heliyon.2024.e33179_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33179_bib25","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e33179_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101623","article-title":"Latin American Network of Coronavirus Disease, Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis","volume":"34","author":"Rodriguez-Morales","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33179_bib27","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e08819","article-title":"Impact of COVID-19 pandemic on 2-[(18)F]FDG PET\/CT imaging work-flow in a single medical institution: comparison among the three Italian waves","volume":"8","author":"Maurea","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2024.e33179_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109621","article-title":"Chest CT in COVID-19 patients: structured vs conventional reporting","volume":"138","author":"Stanzione","year":"2021","journal-title":"Eur. J. Radiol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40477-022-00674-3","article-title":"COVID-19 vaccine-induced lymphadenopathies: incidence, course and imaging features from an ultrasound prospective study","volume":"25","author":"Romeo","year":"2022","journal-title":"J Ultrasound"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33179_bib31","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3748\/wjg.v29.i12.1838","article-title":"Autoimmune liver diseases and SARS-CoV-2","volume":"29","author":"Sgamato","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33179_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00512-20","article-title":"Laboratory diagnosis of COVID-19: current issues and challenges","volume":"58","author":"Tang","year":"2020","journal-title":"J. Clin. Microbiol."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e33179_bib33","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e33179_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.15585\/mmwr.mm6921e1","article-title":"Universal and serial laboratory testing for SARS-CoV-2 at a long-term care skilled nursing facility for veterans - Los Angeles, California","volume":"69","author":"Dora","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib35","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1038\/s41467-020-18611-5","article-title":"Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR","volume":"11","author":"Smyrlaki","year":"2020","journal-title":"Nat. Commun."},{"issue":"589","key":"10.1016\/j.heliyon.2024.e33179_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf2823","article-title":"Lessons from applied large-scale pooling of 133,816 SARS-CoV-2 RT-PCR tests","volume":"13","author":"Barak","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33179_bib37","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1039\/D0CS01411G","article-title":"Radical photoinitiation with LEDs and applications in the 3D printing of composites","volume":"50","author":"Zhang","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33179_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade7923","article-title":"High cell density and high-resolution 3D bioprinting for fabricating vascularized tissues","volume":"9","author":"You","year":"2023","journal-title":"Sci. Adv."},{"issue":"388","key":"10.1016\/j.heliyon.2024.e33179_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0538","article-title":"Rapid and specific detection of asian- and african-lineage Zika viruses","volume":"9","author":"Chotiwan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"14","key":"10.1016\/j.heliyon.2024.e33179_bib40","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.14.2000398","article-title":"An alternative workflow for molecular detection of SARS-CoV-2 - escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020","volume":"25","author":"Fomsgaard","year":"2020","journal-title":"Euro Surveill."},{"issue":"556","key":"10.1016\/j.heliyon.2024.e33179_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7075","article-title":"A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples","volume":"12","author":"Dao Thi","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib42","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41467-021-21627-0","article-title":"Point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP","volume":"12","author":"Bokelmann","year":"2021","journal-title":"Nat. Commun."},{"issue":"39","key":"10.1016\/j.heliyon.2024.e33179_bib43","doi-asserted-by":"crossref","first-page":"24450","DOI":"10.1073\/pnas.2011221117","article-title":"SARS-CoV-2 detection using isothermal amplification and a rapid, inexpensive protocol for sample inactivation and purification","volume":"117","author":"Rabe","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33179_bib44","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/clinchem\/hvaa116","article-title":"Rapid detection of SARS-CoV-2 by low volume real-time single tube reverse transcription recombinase polymerase amplification using an exo probe with an internally linked quencher (Exo-IQ)","volume":"66","author":"Behrmann","year":"2020","journal-title":"Clin. Chem."},{"issue":"6387","key":"10.1016\/j.heliyon.2024.e33179_bib45","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1126\/science.aas8836","article-title":"Field-deployable viral diagnostics using CRISPR-Cas13","volume":"360","author":"Myhrvold","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1373\/clinchem.2019.307835","article-title":"Performance comparison of reverse transcriptases for single-cell studies","volume":"66","author":"Zucha","year":"2020","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(20)30093-8","article-title":"Stability of SARS-CoV-2 in different environmental conditions","volume":"1","author":"Dehbandi","year":"2020","journal-title":"The Lancet Microbe"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib48","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1038\/s41467-020-19258-y","article-title":"An enhanced isothermal amplification assay for viral detection","volume":"11","author":"Qian","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e33179_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13357","article-title":"Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test","volume":"50","author":"Andrey","year":"2020","journal-title":"Eur. J. Clin. Invest."},{"issue":"6495","key":"10.1016\/j.heliyon.2024.e33179_bib50","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1126\/science.abc1227","article-title":"Serology assays to manage COVID-19","volume":"368","author":"Krammer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e33179_bib51","doi-asserted-by":"crossref","first-page":"m2516","DOI":"10.1136\/bmj.m2516","article-title":"Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis","volume":"370","author":"Lisboa Bastos","year":"2020","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28190","article-title":"Development of chemiluminescent lab-on-fiber immunosensors for rapid point-of-care testing of anti-SARS-CoV-2 antibodies and evaluation of longitudinal immune response kinetics following three-dose inactivation virus vaccination","volume":"95","author":"Xu","year":"2023","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib53","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jmv.27287","article-title":"Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity","volume":"94","author":"Dolscheid-Pommerich","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.heliyon.2024.e33179_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2021.113182","article-title":"Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19","volume":"500","author":"Villafa\u00f1e","year":"2022","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17892-0","article-title":"A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation","volume":"11","author":"Muruato","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33179_bib56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/acscentsci.0c00501","article-title":"Assay techniques and test development for COVID-19 diagnosis","volume":"6","author":"Carter","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.heliyon.2024.e33179_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2020.112578","article-title":"Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip","volume":"169","author":"Funari","year":"2020","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.heliyon.2024.e33179_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2021.113005","article-title":"A rapid diagnosis of SARS-CoV-2 using DNA hydrogel formation on microfluidic pores","volume":"177","author":"Kim","year":"2021","journal-title":"Biosens. Bioelectron."},{"issue":"10229","key":"10.1016\/j.heliyon.2024.e33179_bib59","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33179_bib60","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"27","key":"10.1016\/j.heliyon.2024.e33179_bib61","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10249","key":"10.1016\/j.heliyon.2024.e33179_bib62","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"6483","key":"10.1016\/j.heliyon.2024.e33179_bib63","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"6485","key":"10.1016\/j.heliyon.2024.e33179_bib64","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33179_bib65","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.06.003","article-title":"Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters","volume":"128","author":"Kuba","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33179_bib67","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.3201\/eid2812.221160","article-title":"Monkeypox virus detection in different clinical specimen types","volume":"28","author":"Hasso","year":"2022","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib68","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","article-title":"Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting enzyme 2)-independent","volume":"75","author":"Serfozo","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib70","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit. Care"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib71","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib72","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33179_bib73","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01818-18","article-title":"Acute respiratory infection in human dipeptidyl peptidase 4-transgenic mice infected with Middle East respiratory syndrome coronavirus","volume":"93","author":"Iwata-Yoshikawa","year":"2019","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33179_bib74","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1164\/rccm.201502-0299OC","article-title":"Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis","volume":"193","author":"Bardou","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33179_bib75","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.cmi.2024.01.029","article-title":"TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate","volume":"30","author":"Hernandez-Mitre","year":"2024","journal-title":"Clin. Microbiol. Infection\u202f: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"issue":"7909","key":"10.1016\/j.heliyon.2024.e33179_bib76","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41586-022-04661-w","article-title":"A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic","volume":"605","author":"Shapira","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib77","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells","volume":"78","author":"Hoffmann","year":"2020","journal-title":"Mol. Cell."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33179_bib78","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.23062","article-title":"Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection","volume":"50","author":"Lei","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib79","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/14756366.2017.1306521","article-title":"Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication","volume":"32","author":"Kouretova","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e33179_bib80","first-page":"m1295","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib81","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e33179_bib82","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejmech.2016.04.034","article-title":"1'-Homonucleosides and their structural analogues: a review","volume":"118","author":"Wroblewski","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33179_bib83","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/jmv.24678","article-title":"Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials","volume":"88","author":"Elfiky","year":"2016","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.heliyon.2024.e33179_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116958","article-title":"Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV","volume":"238","author":"Elfiky","year":"2019","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33179_bib85","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00044-016-1533-y","article-title":"IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study","volume":"25","author":"Elfiky","year":"2016","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.heliyon.2024.e33179_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33179_bib87","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.909","article-title":"Molnupiravir: a new candidate for COVID-19 treatment","volume":"10","author":"Pourkarim","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e33179_bib89","first-page":"e32","article-title":"Molnupiravir for covid-19 in nonhospitalized patients","volume":"386","author":"Roberfroid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e33179_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074572","article-title":"Molnupiravir and risk of post-acute sequelae of covid-19: cohort study","volume":"381","author":"Xie","year":"2023","journal-title":"BMJ"},{"issue":"10373","key":"10.1016\/j.heliyon.2024.e33179_bib91","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33179_bib92","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev. Res."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e33179_bib93","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e33179_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104899","article-title":"Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status","volume":"158","author":"Antinori","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e33179_bib95","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e33179_bib96","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"21","author":"Chappell","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib97","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.molcel.2016.12.023","article-title":"Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28","volume":"65","author":"Smargon","year":"2017","journal-title":"Mol. Cell."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib98","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2018.02.028","article-title":"Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein","volume":"70","author":"Yan","year":"2018","journal-title":"Mol. Cell."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib99","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","article-title":"Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza","volume":"181","author":"Abbott","year":"2020","journal-title":"Cell"},{"issue":"10238","key":"10.1016\/j.heliyon.2024.e33179_bib100","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib101","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.apsb.2021.10.026","article-title":"Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays","volume":"12","author":"Ma","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib102","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33179_bib103","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e33179_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8778","article-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors","volume":"9","author":"Moghadasi","year":"2023","journal-title":"Sci. Adv."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e33179_bib105","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/14656566.2022.2146493","article-title":"Ensitrelvir as a potential treatment for COVID-19","volume":"23","author":"McCarthy","year":"2022","journal-title":"Expet Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib106","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41467-023-36729-0","article-title":"Identification of SARS-CoV-2 M(pro) inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2","volume":"14","author":"Higashi-Kuwata","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33179_bib107","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and safety of Ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study","volume":"76","author":"Mukae","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"679","key":"10.1016\/j.heliyon.2024.e33179_bib108","doi-asserted-by":"crossref","first-page":"eabq4064","DOI":"10.1126\/scitranslmed.abq4064","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28441","article-title":"Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis","volume":"95","author":"Amani","year":"2023","journal-title":"J. Med. Virol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33179_bib110","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMc2205944","article-title":"Nirmatrelvir-ritonavir and viral load rebound in covid-19","volume":"387","author":"Anderson","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7982","key":"10.1016\/j.heliyon.2024.e33179_bib111","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","article-title":"Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir","volume":"622","author":"Duan","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33179_bib112","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e33179_bib113","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1080\/14656566.2023.2262387","article-title":"Paxlovid as a potential treatment for long COVID","volume":"24","author":"McCarthy","year":"2023","journal-title":"Expet Opin. Pharmacother."},{"issue":"38","key":"10.1016\/j.heliyon.2024.e33179_bib114","doi-asserted-by":"crossref","DOI":"10.1126\/scirobotics.aaz3918","article-title":"Autonomic perspiration in 3D-printed hydrogel actuators","volume":"5","author":"Mishra","year":"2020","journal-title":"Sci. Robot."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e33179_bib115","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33179_bib116","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33179_bib117","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e33179_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.876212","article-title":"Inhibitors of SARS-CoV-2 PLpro","volume":"10","author":"Calleja","year":"2022","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib119","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","article-title":"Crystal structure of SARS-CoV-2 papain-like protease","volume":"11","author":"Gao","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33179_bib121","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.2174\/1386207325666211122123602","article-title":"Potential papain-like protease inhibitors against COVID-19: a comprehensive in silico based review","volume":"25","author":"Agrawal","year":"2022","journal-title":"Comb. Chem. High Throughput Screen."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e33179_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27175620","article-title":"Deciphering the potential of pre and pro-vitamin D of mushrooms against Mpro and PLpro proteases of COVID-19: an in silico approach","volume":"27","author":"Tiwari","year":"2022","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e33179_bib123","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33179_bib124","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00836-9","article-title":"High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors","volume":"12","author":"Zhao","year":"2021","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acsptsci.1c00240","article-title":"Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors","volume":"5","author":"Ma","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib126","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity","volume":"65","author":"Shen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e33179_bib127","first-page":"1","article-title":"Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model","author":"Garnsey","year":"2024","journal-title":"bioRxiv"},{"issue":"6690","key":"10.1016\/j.heliyon.2024.e33179_bib128","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.adm9724","article-title":"Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model","volume":"383","author":"Tan","year":"2024","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.heliyon.2024.e33179_bib129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.addr.2020.11.007","article-title":"Peptide and peptide-based inhibitors of SARS-CoV-2 entry","volume":"167","author":"Schutz","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2024.e33179_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2022.170898","article-title":"A peptide array pipeline for the development of Spike-ACE2 interaction inhibitors","volume":"158","author":"Chopra","year":"2022","journal-title":"Peptides"},{"issue":"40","key":"10.1016\/j.heliyon.2024.e33179_bib131","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2210990119","article-title":"Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein","volume":"119","author":"Yang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib132","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e33179_bib133","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303292120","article-title":"A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein","volume":"120","author":"Thijssen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib134","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","article-title":"Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model","volume":"23","author":"Yan","year":"2013","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33179_bib135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.heliyon.2024.e33179_bib136","first-page":"31324","article-title":"RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","volume":"20","author":"Mehra","year":"2020","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33179_bib137","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33179_bib138","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"129","author":"Channappanavar","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33179_bib139","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33179_bib140","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01174-14","article-title":"Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses","volume":"5","author":"Menachery","year":"2014","journal-title":"mBio"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33179_bib141","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/jmv.25783","article-title":"Clinical features and treatment of COVID-19 patients in northeast Chongqing","volume":"92","author":"Wan","year":"2020","journal-title":"J. Med. Virol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33179_bib142","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1473-3099(20)30198-5","article-title":"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study","volume":"20","author":"Qiu","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e33179_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107843","article-title":"Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms","volume":"225","author":"Huang","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33179_bib144","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1002\/ptr.7209","article-title":"Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID-19), current evidence with systematic review and meta-analysis","volume":"35","author":"Jiang","year":"2021","journal-title":"Phytother Res."},{"key":"10.1016\/j.heliyon.2024.e33179_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106174","article-title":"Timely treatment and higher compliance to traditional Chinese medicine: new influencing factors for reducing severe COVID-19 based on retrospective cohorts in 2020 and 2021","volume":"178","author":"Zhang","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2024.e33179_bib146","article-title":"Traditional Chinese medicine for COVID-19 treatment","volume":"155","author":"Ren","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2024.e33179_bib147","article-title":"Use of traditional Chinese medicine for the treatment and prevention of COVID-19 and rehabilitation of COVID-19 patients: an evidence mapping study","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e33179_bib148","article-title":"Successful treatment of subacute thyroiditis after recombinant COVID-19 vaccination using traditional Chinese medicine: a case report","volume":"14","author":"Zhao","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.heliyon.2024.e33179_bib149","article-title":"Treatment of COVID-19 by monoclonal antibodies and the traditional Chinese medicine","volume":"15","author":"Ling","year":"2022","journal-title":"Med Nov Technol Devices"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33179_bib150","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33179_bib151","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.chembiol.2024.03.008","article-title":"SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs","volume":"31","author":"Iketani","year":"2024","journal-title":"Cell Chem. Biol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024092107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024092107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:56:10Z","timestamp":1790542570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024092107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":151,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024092107"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33179","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33179"}}